Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Detalles Bibliográficos
Autores principales: Gavriatopoulou, Maria, Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Papatheodorou, Athanasios, Kanellias, Nikolaos, Migkou, Magdalini, Fotiou, Despina, Dialoupi, Ioanna, Roussou, Maria, Kokkali, Nikoletta-Aikaterini, Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052253/
https://www.ncbi.nlm.nih.gov/pubmed/32123158
http://dx.doi.org/10.1038/s41408-020-0297-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052253/
https://www.ncbi.nlm.nih.gov/pubmed/32123158
http://dx.doi.org/10.1038/s41408-020-0297-2

Ejemplares similares